Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;1(1):5-14.
doi: 10.1159/000336977. Epub 2012 Mar 28.

2012 European thyroid association guidelines for metastatic medullary thyroid cancer

M Schlumberger  1 , L Bastholt  2 , H Dralle  3 , B Jarzab  4 , F Pacini  5 , J W A Smit  6 ; European Thyroid Association Task Force
Affiliations

2012 European thyroid association guidelines for metastatic medullary thyroid cancer

M Schlumberger et al. Eur Thyroid J. 2012 Apr.

Erratum in

  • Eur Thyroid J. 2012;1(2):54

Abstract

Distant metastases are the main cause of death in patients with medullary thyroid cancer (MTC). These 21 recommendations focus on MTC patients with distant metastases and a detailed follow-up protocol of patients with biochemical or imaging evidence of disease, selection criteria for treatment, and treatment modalities, including local and systemic treatments based on the results of recent trials. Asymptomatic patients with low tumor burden and stable disease may benefit from local treatment modalities and can be followed up at regular intervals of time. Imaging is usually performed every 6-12 months, or at longer intervals of time depending on the doubling times of serum calcitonin and carcinoembryonic antigen levels. Patients with symptoms, large tumor burden and progression on imaging should receive systemic treatment. Indeed, major progress has recently been achieved with novel targeted therapies using kinase inhibitors directed against RET and VEGFR, but further research is needed to improve the outcome of these patients.

Keywords: Medullary thyroid cancer; Metastases; Rearranged during transfection mutation; Tyrosine kinase inhibitors.

PubMed Disclaimer

References

    1. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RT, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA., Jr Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565–612. - PubMed
    1. Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, Liberati A, O'Connell D, Oxman AD, Phillips B, Schünemann H, Edejer TT, Vist GE, Williams JW, Jr, GRADE Working Group Grading quality of evidence and strength of recommendations. BMC Health Serv Res. 2004;22(4):38. - PMC - PubMed
    1. Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666–673. - PubMed
    1. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schünemann H. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006;129:174–181. - PubMed
    1. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:22–32. - PubMed